Literature DB >> 28286210

Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis.

Patrik Nasr1, Mikael F Forsgren2, Simone Ignatova3, Nils Dahlström4, Gunnar Cedersund5, Olof Dahlqvist Leinhard6, Bengt Norén7, Mattias Ekstedt1, Peter Lundberg8, Stergios Kechagias9.   

Abstract

It is possible to estimate hepatic triglyceride content by calculating the proton density fat fraction (PDFF), using proton magnetic resonance spectroscopy (1H-MRS), instead of collecting and analyzing liver biopsy specimens to detect steatosis. However, the current PDFF cut-off value (5%) used to define steatosis by magnetic resonance was derived from studies that did not use histopathology as the reference standard. We performed a prospective study to determine the accuracy of 1H-MRS PDFF in the measurement of steatosis using histopathology analysis as the standard. We collected clinical, serologic, 1H-MRS PDFF, and liver biopsy data from 94 adult patients with increased levels of liver enzymes (≥6 mo) referred to the Department of Gastroenterology and Hepatology at Linköping University Hospital in Sweden from 2007 through 2014. Steatosis was graded using the conventional histopathology method and fat content was quantified in biopsy samples using stereologic point counts (SPCs). We correlated the 1H-MRS PDFF findings with SPCs (r = 0.92; P < .001). 1H-MRS PDFF results correlated with histopathology results (ρ = 0.87; P < .001), and SPCs correlated with histopathology results (ρ = 0.88; P < .001). All 25 subjects with PDFF values of 5.0% or more had steatosis based on histopathology findings (100% specificity for PDFF). However, of 69 subjects with PDFF values less than 5.0% (negative result), 22 were determined to have steatosis based on histopathology findings (53% sensitivity for PDFF). Reducing the PDFF cut-off value to 3.0% identified patients with steatosis with 100% specificity and 79% sensitivity; a PDFF cut-off value of 2.0% identified patients with steatosis with 94% specificity and 87% sensitivity. These findings might be used to improve noninvasive detection of steatosis.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic Tests; NASH; Nonalcoholic Fatty Liver Disease

Mesh:

Substances:

Year:  2017        PMID: 28286210     DOI: 10.1053/j.gastro.2017.03.005

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

1.  Measurement of spleen fat on MRI-proton density fat fraction arises from reconstruction of noise.

Authors:  Cheng William Hong; Gavin Hamilton; Catherine Hooker; Charlie C Park; Calvin Andrew Tran; Walter C Henderson; Jonathan C Hooker; Soudabeh Fazeli Dehkordy; Jeffrey B Schwimmer; Scott B Reeder; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2019-10

2.  Diagnosis of Nonalcoholic Steatohepatitis Without Liver Biopsy.

Authors:  Beatrice L Madrazo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-06

Review 3.  Lessons learnt from pathologic imaging correlation in the liver: an historical perspective.

Authors:  Yvonne Purcell; Pauline Copin; Valérie Paradis; Valérie Vilgrain; Maxime Ronot
Journal:  Br J Radiol       Date:  2019-01-10       Impact factor: 3.039

4.  Noise properties of proton density fat fraction estimated using chemical shift-encoded MRI.

Authors:  Nathan T Roberts; Diego Hernando; James H Holmes; Curtis N Wiens; Scott B Reeder
Journal:  Magn Reson Med       Date:  2018-01-10       Impact factor: 4.668

5.  A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial.

Authors:  Mads J Skytte; Amirsalar Samkani; Amy D Petersen; Mads N Thomsen; Arne Astrup; Elizaveta Chabanova; Jan Frystyk; Jens J Holst; Henrik S Thomsen; Sten Madsbad; Thomas M Larsen; Steen B Haugaard; Thure Krarup
Journal:  Diabetologia       Date:  2019-07-23       Impact factor: 10.122

Review 6.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

7.  Accuracy of common proton density fat fraction thresholds for magnitude- and complex-based chemical shift-encoded MRI for assessing hepatic steatosis in patients with obesity.

Authors:  Guilherme Moura Cunha; Tydus T Thai; Gavin Hamilton; Yesenia Covarrubias; Alexandra Schlein; Michael S Middleton; Curtis N Wiens; Alan McMillan; Rashmi Agni; Luke M Funk; Guilherme M Campos; Santiago Horgan; Garth Jacobson; Tanya Wolfson; Anthony Gamst; Jeffrey B Schwimmer; Scott B Reeder; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2020-03

8.  Effect of noise and estimator type on bias for analysis of liver proton density fat fraction.

Authors:  Edward M Lawrence; Nathan T Roberts; Diego Hernando; Lu Mao; Scott B Reeder
Journal:  Magn Reson Imaging       Date:  2020-10-02       Impact factor: 2.546

9.  Liver Fat Reduction After Gastric Banding and Associations with Changes in Insulin Sensitivity and β-Cell Function.

Authors:  Anny H Xiang; Mayra P Martinez; Enrique Trigo; Kristina M Utzschneider; Melanie Cree-Green; Silva A Arslanian; David A Ehrmann; Sonia Caprio; Passant H I H Mohamed; Darryl H Hwang; Namir Katkhouda; Krishna S Nayak; Thomas A Buchanan
Journal:  Obesity (Silver Spring)       Date:  2021-05-26       Impact factor: 9.298

10.  Association between cumulative childhood blood lead exposure and hepatic steatosis in young Mexican adults.

Authors:  Larissa Betanzos-Robledo; Alejandra Cantoral; Karen E Peterson; Howard Hu; Mauricio Hernández-Ávila; Wei Perng; Erica Jansen; Adrienne S Ettinger; Adriana Mercado-García; Maritsa Solano-González; Brisa Sánchez; Martha M Téllez-Rojo
Journal:  Environ Res       Date:  2021-03-07       Impact factor: 6.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.